Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 5489057, 6 pages
https://doi.org/10.1155/2017/5489057
Research Article

The Impact of Homocysteine, Vitamin B12, and Vitamin D Levels on Functional Outcome after First-Ever Ischaemic Stroke

1General Hospital, Unit of Neurology, Svetog Save Street No. 33, Berane, Montenegro
2Faculty of Medicine, University of Belgrade, Neurology Clinic, Clinical Center of Serbia, Dr. Subotica Street No. 6, 11 000 Belgrade, Serbia
3Faculty for Special Education and Rehabilitation, University of Belgrade, Visokog Stevana Street No. 2, 11 000 Belgrade, Serbia

Correspondence should be addressed to Dragan M. Pavlović; moc.liamtoh@35civolvapd

Received 11 January 2017; Revised 4 March 2017; Accepted 9 March 2017; Published 23 March 2017

Academic Editor: Vida Demarin

Copyright © 2017 Merdin Markišić et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Levenson, “Psychiatric issues in neurology, part I: stroke,” Primary Psychiatry, vol. 14, no. 9, pp. 37–40, 2007. View at Google Scholar · View at Scopus
  2. A. Bunevicius, G. Iervasi, and R. Bunevicius, “Neuroprotective actions of thyroid hormones and low-T3 syndrome as a biomarker in acute cerebrovascular disorders,” Expert Review of Neurotherapeutics, vol. 15, no. 3, pp. 315–326, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. O'Donnell, D. Xavier, L. Liu et al., “Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study,” The Lancet, vol. 376, no. 9735, pp. 112–123, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. L. B. Goldstein, C. D. Bushnell, R. J. Adams et al., “Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, vol. 42, no. 2, pp. 517–584, 2011. View at Google Scholar
  5. G. W. Petty, R. D. Brown Jr., J. P. Whisnant, J. D. Sicks, W. M. O'Fallon, and D. O. Wiebers, “Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence,” Stroke, vol. 31, no. 5, pp. 1062–1068, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. L. N. Joseph, V. L. Babikian, N. C. Allen, and M. R. Winter, “Risk factor modification in stroke prevention: the experience of a stroke clinic,” Stroke, vol. 30, no. 1, pp. 16–20, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. K. L. Keene, W. M. Chen, F. Chen et al., “Genetic associations with plasma B12, B6, and folate levels in an ischemic stroke population from the vitamin intervention for stroke prevention (VISP) trial,” Frontiers in Public Health, vol. 2, article 112, 2014. View at Google Scholar
  8. Y. He, Y. Li, Y. Chen, L. Feng, and Z. Nie, “Homocysteine level and risk of different stroke types: a meta-analysis of prospective observational studies,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 24, no. 11, pp. 1158–1165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. L. E. Kelemen, S. S. Anand, R. A. Hegele et al., “Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians,” Atherosclerosis, vol. 176, no. 2, pp. 361–370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. I. M. Graham, L. E. Daly, H. M. Refsum et al., “Plasma homocysteine as a risk factor for vascular disease The European Concerted Action Project,” The Journal of the American Medical Association, vol. 277, pp. 1775–1781, 1997. View at Google Scholar
  11. O. Nygård, J. E. Nordrehaug, H. Refsum, P. M. Ueland, M. Farstad, and S. E. Vollset, “Plasma homocysteine levels and mortality in patients with coronary artery disease,” The New England Journal of Medicine, vol. 337, no. 4, pp. 230–236, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Pieters, J. Staals, I. Knottnerus et al., “Periventricular white matter lucencies relate to low vitamin B12 levels in patients with small vessel stroke,” Stroke, vol. 40, no. 5, pp. 1623–1626, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Saposnik, “The role of vitamin B in stroke prevention: a journey from observational studies to clinical trials and critique of the VITAmins TO Prevent Stroke (VITATOPS),” Stroke, vol. 42, no. 3, pp. 838–842, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. E. J. Norman, “Urinary methylmalonic acid/creattnine ratio: a gold standard test for tissue vitamin B12 deficiency,” Journal of the American Geriatrics Society, vol. 47, no. 9, pp. 1158–1159, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. J. D. Spence, “Metabolic vitamin B12 deficiency: a missed opportunity to prevent dementia and stroke,” Nutrition Research, vol. 36, no. 2, pp. 109–116, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Aparicio-Ugarriza, G. Palacios, M. Alder, and M. González-Gross, “A review of the cut-off points for the diagnosis of vitamin B12 deficiency in the general population,” Clinical Chemistry and Laboratory Medicine, vol. 53, no. 8, pp. 1149–1159, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. A. S. Dusso and M. Tokumoto, “Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease,” Kidney International, vol. 79, no. 7, pp. 715–729, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Kienreich, M. Grübler, A. Tomaschitz et al., “Vitamin D, arterial hypertension & cerebrovascular disease,” Indian Journal of Medical Research, vol. 137, no. 4, pp. 669–679, 2013. View at Google Scholar · View at Scopus
  19. K.-Y. Park, P.-W. Chung, Y. B. Kim et al., “Serum vitamin D status as a predictor of prognosis in patients with acute ischemic stroke,” Cerebrovascular Diseases, vol. 40, no. 1-2, pp. 73–80, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. Q. Sun, A. Pan, F. B. Hu, J. E. Manson, and K. M. Rexrode, “25-hydroxyvitamin D levels and the risk of stroke: a prospective study and meta-analysis,” Stroke, vol. 43, no. 6, pp. 1470–1477, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Y. Leung, Y. Han, C. W. Sing et al., “Serum 25-hydroxyvitamin D and the risk of stroke in Hong Kong Chinese,” Thrombosis and Haemostasis, vol. 117, no. 1, pp. 158–163, 2017. View at Publisher · View at Google Scholar
  22. A. Zittermann, S. Iodice, S. Pilz, W. B. Grant, V. Bagnardi, and S. Gandini, “Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies,” American Journal of Clinical Nutrition, vol. 95, no. 1, pp. 91–100, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Ren, Y. Gu, L. Zhu et al., “The effect of cigarette smoking on Vitamin D level and depression in male patients with acute ischemic stroke,” Comprehensive Psychiatry, vol. 65, pp. 9–14, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. VITATOPS Trial Study Group, “B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins to prevent stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial,” Lancet Neurology, vol. 9, no. 9, pp. 855–865, 2010. View at Google Scholar
  25. H.-M. Kwon, Y.-S. Lee, H.-J. Bae, and D.-W. Kang, “Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke,” Stroke, vol. 45, no. 3, pp. 871–873, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Daubail, A. Jacquin, J.-C. Guilland et al., “Serum 25-hydroxyvitamin D predicts severity and prognosis in stroke patients,” European Journal of Neurology, vol. 20, no. 1, pp. 57–61, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. W. N. Kernan, B. B. Ovbiagele, H. R. Black et al., “Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, vol. 45, no. 7, pp. 2160–2236, 2014. View at Google Scholar
  28. European Stroke Organisation (ESO) Executive Committee and ESO Writing Committee, “Guidelines for management of ischaemic stroke and transient ischaemic attack 2008,” Cerebrovascular Diseases, vol. 25, no. 5, pp. 457–507, 2008. View at Google Scholar
  29. J. Rankin, “Cerebral vascular accidents in patients over the age of 60: II. Prognosis,” Scottish Medical Journal, vol. 2, no. 5, pp. 200–215, 1957. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Bonita and R. Beaglehole, “Modification of rankin scale: recovery of motor function after stroke,” Stroke, vol. 19, no. 12, pp. 1497–1500, 1988. View at Publisher · View at Google Scholar · View at Scopus
  31. J. L. Saver, “Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices,” Stroke, vol. 42, no. 8, pp. 2356–2362, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. F. A. Wollenweber, V. Zietemann, A. Gschwendtner, C. Opherk, and M. Dichgans, “Subclinical hyperthyroidism is a risk factor for poor functional outcome after ischemic stroke,” Stroke, vol. 44, no. 5, pp. 1446–1448, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Paci, L. Nannetti, P. D'Ippolito, and B. Lombardi, “Outcomes from ischemic stroke subtypes classified by the Oxfordshire Community Stroke Project: a systematic review,” European Journal of Physical and Rehabilitation Medicine, vol. 47, no. 1, pp. 19–23, 2011. View at Google Scholar · View at Scopus
  34. C. E. Skilbeck, D. T. Wade, R. L. Hewer, and V. A. Wood, “Recovery after stroke,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 46, no. 1, pp. 5–8, 1983. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Lee, K.-S. Hong, S.-C. Chang, and J. L. Saver, “Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis,” Stroke, vol. 41, no. 6, pp. 1205–1212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. X.-Q. Wu, J. Ding, A.-Y. Ge, X. Wang, and W. Fan, “Acute phase homocysteine related to severity and outcome of atherothrombotic stroke—reply,” European Journal of Internal Medicine, vol. 25, no. 1, p. e15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. E. H. Mizrahi, Y. Fleissig, M. Arad, and A. Adunsky, “Plasma homocysteine level and functional outcome of patients with ischemic stroke,” Archives of Physical Medicine and Rehabilitation, vol. 86, no. 1, pp. 60–63, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Wu, L. Wang, W. Teng, K. Huang, and X. Shang, “Correlation of post-stroke fatigue with glucose, homocysteine and functional disability,” Acta Neurologica Scandinavica, vol. 131, no. 6, pp. 400–404, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Y. Z. Youssef, O. A. Mojiminiyi, and N. A. Abdella, “Plasma concentrations of C-reactive protein and total homocysteine in relation to the severity and risk factors for cerebrovascular disease,” Translational Research, vol. 150, no. 3, pp. 158–163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. W.-J. Tu, S.-J. Zhao, T.-G. Liu, D.-G. Yang, and H. Chen, “Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke,” Neurological Research, vol. 35, no. 9, pp. 912–921, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. X. Men, J. Li, B. Zhang, L. Zhang, H. Li, and Z. Lu, “Homocysteine and C-reactive protein associated with progression and prognosis of intracranial branch atheromatous disease,” PloS ONE, vol. 8, no. 9, Article ID e73030, 2013. View at Google Scholar · View at Scopus
  42. G. Saposnik, J. G. Ray, P. Sheridan, M. McQueen, and E. Lonn, “Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial,” Stroke, vol. 40, no. 4, pp. 1365–1372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. G. Saposnik, “Meta analysis suggests that folic acid supplementation does not reduce risk of stroke, but there may be some benefit when given in combination with vitamins B6 and B12 and in primary prevention,” Evidence-Based Medicine, vol. 15, no. 6, pp. 168–170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. O. Stanger, W. Herrmann, K. Pietrzik et al., “DACH-LIGA homocystein (German, Austrian and Swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations,” Clinical Chemistry and Laboratory Medicine, vol. 41, no. 11, pp. 1392–1403, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Faeh, A. Chiolero, and F. Paccaud, “Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about it?” Swiss Medical Weekly, vol. 136, no. 47-48, pp. 745–756, 2006. View at Google Scholar · View at Scopus
  46. H. Refsum, E. Nurk, A. D. Smith et al., “The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease,” Journal of Nutrition, vol. 136, supplement 6, pp. 1731S–1740S, 2006. View at Google Scholar · View at Scopus
  47. Homocysteine Studies Collaboration, “Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis,” The Journal of the American Medical Association, vol. 288, no. 16, pp. 2015–2022, 2002. View at Google Scholar
  48. H. N. Hodis, W. J. Mack, L. Dustin et al., “High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial,” Stroke, vol. 40, no. 3, pp. 730–736, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Obeid, J. Jung, J. Falk et al., “Serum vitamin B12 not reflecting vitamin B12 status in patients with type 2 diabetes,” Biochimie, vol. 95, no. 5, pp. 1056–1061, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. S. P. Stabler, “Screening the older population for cobalamin (vitamin B12) deficiency,” Journal of the American Geriatrics Society, vol. 43, no. 11, pp. 1290–1297, 1995. View at Publisher · View at Google Scholar · View at Scopus
  51. A. L. C. Schneider, P. L. Lutsey, E. Selvin et al., “Vitamin D, vitamin D binding protein gene polymorphisms, race and risk of incident stroke: the Atherosclerosis Risk in Communities (ARIC) study,” European Journal of Neurology, vol. 22, no. 8, pp. 1220–1227, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Daubail, A. Jacquin, J.-C. Guilland et al., “Association between serum concentration of vitamin D and 1-year mortality in stroke patients,” Cerebrovascular Diseases, vol. 37, no. 5, pp. 364–367, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Turetsky, R. P. Goddeau Jr., and N. Henninger, “Low serum vitamin D is independently associated with larger lesion volumes after ischemic stroke,” Journal of Stroke and Cerebrovascular Diseases, vol. 24, no. 7, pp. 1555–1563, 2015. View at Publisher · View at Google Scholar · View at Scopus